Hypothermic effect of antihypoxant 2-aminobenzotiazole

Abstract

BACKGROUND: The compound 2-aminobenzothiazole (2-ABT), which has a proven antihypoxic effect, was studied at the Department of Pharmacology of the Kirov Military Medical Academy. The mechanism of action of this substance is partially associated with the central action, and its protective effect may be due to the general hypothermic effect. AIM: To determine the effect of 2-ABT on body temperature. MATERIALS AND METHODS: Twenty-four male adult white outbred mice were studied. Moreover, 2-ABT was dissolved in 0.9% sodium chloride solution and administered intraperitoneally to mice at doses of 32.5 mg/kg (with proven antihypoxic effect), 21.7 mg/kg, and 10.8 mg/kg. Rectal temperature was obtained with an electronic thermometer (DT-623, China) before administration of the test substance and at 5, 30, and 60 min after the injection. RESULTS: Compound 2-ABT has a pronounced dose-dependent hypothermic effect. This effect is maximally expressed in a dose in which the compound has a proven antihypoxic property — 32.5 mg/kg. The hypothermic effect was evident within 5 min after administration. Additionally, the maximum decrease in body temperature was observed after 30 min, whereas the effect persisted for 1 h. CONCLUSIONS: 2-ABT may be a promising compound for developing a drug for drug-induced (controlled) hypothermia.

Keywords

hypothermia / antihypoxants / thermoregulation / 2-aminobenzothiazole

References

[1] Shabanov PD, Zarubina IV, Novikov VE, Tsygan VN. Metabolic correctors of hypoxia. Belevitin AB, editor. Saint Petersburg: Inform-Novigator; 2010. 912 p. (In Russ.)

[2] Шабанов П.Д., Зарубина И.В., Новиков В.Е., Цыган В.Н. Метаболические корректоры гипоксии / под ред. А.Б. Белевитина. Санкт-Петербург: Информ-Новигатор, 2010. 912 с.

[3] Patent RUS N 2776219 C1/14.07.2022. Marysheva VV, Shabanov PD, Mikheev VV. Method of increasing life expectancy in experiment under hypercapnic hypoxia. (In Russ.)

[4] Патент РФ № 2776219 C1/14.07.2022. Марышева В.В., Шабанов П.Д., Михеев В.В. Способ повышения продолжительности жизни в эксперименте при гиперкапнической гипоксии.

[5] GOST 33215-2014 from 01.07.2016. Guidelines for the maintenance and care of laboratory animals. Rules for equipment of premises and organisation of procedures. Moscow: Standardinform; 2019. 11 p. (In Russ.)

[6] ГОСТ 33215-2014 от 01.07.2016. Руководство по содержанию и уходу за лабораторными животными. Правила оборудования помещений и организации процедур. Москва: Стандартинформ, 2019. 11 с.

[7] GOST 33216-2014 from 01.07.2016. Guidelines for the maintenance and care of laboratory animals. Rules for maintenance and care of laboratory rodents and rabbits. Moscow: Standardinform; 2019. 8 p. (In Russ.)

[8] ГОСТ 33216–2014 от 01.07.2016. Руководство по содержанию и уходу за лабораторными животными. Правила содержания и ухода за лабораторными грызунами и кроликами. Москва: Стандартинформ, 2019. 8 с.

[9] Dikmanov VV, Novikov VE, Marysheva VV, Shabanov PD. Antihypoxic properties of triazinoindol derivatives. Reviews on Clinical Pharmacology and Drug Therapy. 2011;9(3):60–64. EDN: OUNJPD

[10] Дикманов В.В., Новиков В.Е., Марышева В.В., Шабанов П.Д. Антигипоксические свойства производных тиазолоиндола // Обзоры по клинической фармакологии и лекарственной терапии. 2011. Т. 9, № 3. С. 60–64. EDN: OUNJPD

[11] Sosin DV. Selenium-containing metal complex compounds in acute exogenous hypoxia: speciality [dissertation abstract]. Saint Petrsburg, 2015. 22 p. (In Russ.)

[12] Сосин Д.В. Селенсодержащие металлокомплексные соединения при острой экзогенной гипоксии: автореф. дис. … д-ра мед. наук. Санкт-Петербург, 2015. 22 с.

[13] Skripka MO, Maltsev DV, Spasov AA, Perfiliev MA. Pharmacological analysis of the mechanisms of action of a ouinoxaline derivative with anxiolytic properties. Journal of Volgograd State Medical University. 2022;19(3):134–140. EDN: GEYFDE doi: 10.19163/1994-9480-2022-19-3-134-140

[14] Скрипка М.О., Мальцев Д.В., Спасов А.А., Перфильев М.А. Фармакологический анализ механизмов действия производного хиноксалина с анксиолитической активностью // Вестник Волгоградского государственного медицинского университета. 2022. Т. 19, № 3. С. 134–140. EDN: GEYFDE doi: 10.19163/1994-9480-2022-19-3-134-140

[15] Lin MT, Wang HS, Wang Z, Chern YF. Haloperidol produces hypothermic effects in rats. Experientia. 1979;35(11):1469–1470. doi: 10.1007/BF01962790

[16] Lin M.T., Wang H.S., Wang Z., Chern Y.F. Haloperidol produces hypothermic effects in rats // Experientia. 1979. Vol. 35, N 11. P. 1469–1470. doi: 10.1007/BF01962790

[17] Khabriev RU, editor. Manual on experimental (preclinical) study of new pharmacological substances. 2nd ed., rev. and suppl. Moscow: Medicine, 2005. 832 p. (In Russ.)

[18] Руководство по экспериментальному (доклиническому) изучению новых фармакологических веществ. 2-е изд., перераб. и доп. / под ред. Р.У. Хабриева. Москва: Медицина, 2005. 832 с.

[19] Choukér A, Ngo-Ahn TJ, Biesbroek R, et al. European space agency’s hibernation (torpor) strategy for deep space missions: Linking biology to engineering. Neurosci Biobehav Rev. 2021;131:618–626. doi: 10.1016/j.neubiorev.2021.09.054

[20] Choukér A., Ngo-Ahn T.J., Biesbroek R., et al. European space agency’s hibernation (torpor) strategy for deep space missions: Linking biology to engineering // Neurosci Biobehav Rev. 2021. Vol. 131. P. 618–626. doi: 10.1016/j.neubiorev.2021.09.054

RIGHTS & PERMISSIONS

Eco-Vector